Avanos Medical (AVNS) Long-Term Deferred Tax (2014 - 2026)

Avanos Medical (AVNS) has 13 years of Long-Term Deferred Tax data on file, last reported at $33.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 32.0% year-over-year to $33.0 million; the trailing twelve-month figure through Mar 2026 stood at $33.0 million (up 32.0% YoY), and the FY2025 full-year result was $33.1 million, up 32.93% from the prior year.
• Long-Term Deferred Tax steadied at $33.0 million in Q1 2026, from $33.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $33.1 million in Q4 2025 to a low of $4.3 million in Q3 2023.
• A 5-year average of $14.3 million and a median of $10.9 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax slumped 82.07% in 2022 and surged 301.59% in 2025, its largest moves.
• Tracing AVNS's Long-Term Deferred Tax over 5 years: stood at $4.6 million in 2022, then soared by 41.3% to $6.5 million in 2023, then surged by 283.08% to $24.9 million in 2024, then surged by 32.93% to $33.1 million in 2025, then declined by 0.3% to $33.0 million in 2026.
• Business Quant data shows AVNS's Long-Term Deferred Tax at $33.0 million in Q1 2026, $33.1 million in Q4 2025, and $25.3 million in Q3 2025.